CHICAGO — The antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) yielded high response rates with glorious sturdiness in patients with blastic plasmacytoid dendritic cell Read More
Tags :Standard
You invent no longer bag permission to entry "http://www.medpagetoday.com/meetingcoverage/sgo/114673" on this server. Reference #18.27257e68.1742148749.6c03c75 https://Read More
itel, a leading cell phone designate, is determined to shake up the gaming world with the launch of its newest flagship system, Read More
Meeting Protection > AACR — Adagrasib plus cetuximab ends in responses in a single-third of sufferers, median OS of 15.9 months by Charles Bankhead, Senior Read More
SAN DIEGO -- A time-restricted, centered combination tremendously improved survival when put next with chemoimmunotherapy in fit power lymphocytic leukemia (CLL) patients Read More
Please enable JS and disable any advert blockerLearn ExtraRead More
Meeting Coverage > ASCO — "We may well presumably fair restful firmly end the door on one-size-suits-all treatment," says ASCO educated by Ian Ingram, Read More
